Tuesday, April 22, 2014
GSK and Theravance Announce Phase III Study of Fluticasone Furoate/Vilanterol in COPD Commenced to Support Potential Future Filing in Japan
Monday, April 21, 2014
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
Tuesday, April 15, 2014
Theravance to Report First Quarter 2014 Financial Results on May 6, 2014
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
We partner with pharmaceutical companies to accelerate development and commercialization of our product candidates.
Every day at Theravance, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance discovers, develops and brings important medicines to patients by: